Smith & Nephew struck an agreement last week to buy CartiHeal for $180 million upfront to expand its range of sports medicine technologies.
CartiHeal received U.S. approval for its knee implant Agili-C last year, but the progress has been overshadowed by Bioventus’ protracted buyout bid, which ultimately fell apart and opened the door to Smith & Nephew.
The British medtech company seized the opportunity, agreeing to pay an additional $150 million tied to financial performance to slot Agili-C into its fast-growing sports medicine unit.

You can see a video on the Agili-C story here: